Literature DB >> 16912313

Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.

Andrew J Macadam1, Geraldine Ferguson, David M Stone, Janet Meredith, Sarah Knowlson, Ghazi Auda, Jeffrey W Almond, Philip D Minor.   

Abstract

The global eradication of poliomyelitis caused by wild-type virus is likely to be completed within the next few years, despite immense logistic and political difficulties, and may ultimately be followed by the cessation of vaccination. However, the existing live-attenuated vaccines have the potential to revert to virulence, causing occasional disease, and viruses can be shed by immunocompromised individuals for prolonged periods of time. Moreover, several outbreaks of poliomyelitis have been shown to be caused by viruses derived from the Sabin vaccine strains. The appearance of such strains depends on the prevailing circumstances but poses a severe obstacle to strategies for stopping vaccination. Vaccine strains that are incapable of reversion at a measurable rate would provide a possible solution. Here, we describe the constructions of strains of type 3 poliovirus that are stabilized by the introduction of four mutations in the 5' noncoding region compared to the present vaccine. The strains are genetically and phenotypically stable under conditions where the present vaccine loses the attenuating mutation in the 5' noncoding region completely. Type 1 and type 2 strains in which the entire 5' noncoding regions of Sabin 1 and Sabin 2 were replaced exactly with that of one of the type 3 strains were also constructed. The genetic stability of 5' noncoding regions of these viruses matched that of the type 3 strains, but significant phenotypic reversion occurred, illustrating the potential limitations of a rational approach to the genetic stabilization of live RNA virus vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912313      PMCID: PMC1563845          DOI: 10.1128/JVI.00370-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Strong inclination toward transition mutation in nucleotide substitutions by poliovirus replicase.

Authors:  S Kuge; N Kawamura; A Nomoto
Journal:  J Mol Biol       Date:  1989-05-05       Impact factor: 5.469

2.  The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3.

Authors:  P D Minor; G Dunn; D M Evans; D I Magrath; A John; J Howlett; A Phillips; G Westrop; K Wareham; J W Almond
Journal:  J Gen Virol       Date:  1989-05       Impact factor: 3.891

3.  New model for the secondary structure of the 5' non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence.

Authors:  M A Skinner; V R Racaniello; G Dunn; J Cooper; P D Minor; J W Almond
Journal:  J Mol Biol       Date:  1989-05-20       Impact factor: 5.469

4.  Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.

Authors:  S R Pollard; G Dunn; N Cammack; P D Minor; J W Almond
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors:  G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

6.  Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.

Authors:  S van der Werf; J Bradley; E Wimmer; F W Studier; J J Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

7.  An inducible mammalian amber suppressor: propagation of a poliovirus mutant.

Authors:  J M Sedivy; J P Capone; U L RajBhandary; P A Sharp
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

8.  Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.

Authors:  D M Evans; G Dunn; P D Minor; G C Schild; A J Cann; G Stanway; J W Almond; K Currey; J V Maizel
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

9.  Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child.

Authors:  L E Davis; D Bodian; D Price; I J Butler; J H Vickers
Journal:  N Engl J Med       Date:  1977-08-04       Impact factor: 91.245

10.  Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.

Authors:  Calman MacLennan; Glynis Dunn; Aarnoud P Huissoon; Dinakantha S Kumararatne; Javier Martin; Paula O'Leary; Ronald A Thompson; Husam Osman; Philip Wood; Philip Minor; David J Wood; Deenan Pillay
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

View more
  26 in total

Review 1.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

2.  Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization.

Authors:  Jennifer L Konopka-Anstadt; Ray Campagnoli; Annelet Vincent; Jing Shaw; Ling Wei; Nhien T Wynn; Shane E Smithee; Erika Bujaki; Ming Te Yeh; Majid Laassri; Tatiana Zagorodnyaya; Amy J Weiner; Konstantin Chumakov; Raul Andino; Andrew Macadam; Olen Kew; Cara C Burns
Journal:  NPJ Vaccines       Date:  2020-03-20       Impact factor: 7.344

Review 3.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

4.  Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons.

Authors:  Cara C Burns; Ray Campagnoli; Jing Shaw; Annelet Vincent; Jaume Jorba; Olen Kew
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

5.  A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates.

Authors:  Haichen Song; Gloria Ramirez Nieto; Daniel R Perez
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

6.  An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys.

Authors:  Minetaro Arita; Noriyo Nagata; Naoko Iwata; Yasushi Ami; Yuriko Suzaki; Katsumi Mizuta; Takuya Iwasaki; Tetsutaro Sata; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

7.  Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.

Authors:  Cara C Burns; Jing Shaw; Jaume Jorba; David Bukbuk; Festus Adu; Nicksy Gumede; Muhammed Ali Pate; Emmanuel Ade Abanida; Alex Gasasira; Jane Iber; Qi Chen; Annelet Vincent; Paul Chenoweth; Elizabeth Henderson; Kathleen Wannemuehler; Asif Naeem; Rifqiyah Nur Umami; Yorihiro Nishimura; Hiroyuki Shimizu; Marycelin Baba; Adekunle Adeniji; A J Williams; David R Kilpatrick; M Steven Oberste; Steven G Wassilak; Oyewale Tomori; Mark A Pallansch; Olen Kew
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

8.  Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

Authors:  Joseph E Blaney; Neeraj S Sathe; Laura Goddard; Christopher T Hanson; Tammy A Romero; Kathryn A Hanley; Brian R Murphy; Stephen S Whitehead
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

9.  Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.

Authors:  Sabine M G van der Sanden; Weilin Wu; Naomi Dybdahl-Sissoko; William C Weldon; Paula Brooks; Jason O'Donnell; Les P Jones; Cedric Brown; S Mark Tompkins; M Steven Oberste; Jon Karpilow; Ralph A Tripp
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

10.  Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Amanda Wilkinson; Ananda S Bandyopadhyay; Jennifer L Konopka-Anstadt; Cara C Burns; M Steven Oberste; Steven G F Wassilak; Kamran Badizadegan; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-11-10       Impact factor: 4.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.